BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE
Generic: BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE
Edenbridge Pharmaceuticals LLC.Manufacturer
ORALRoute
BISOPROLOL FUMARATEActive Substance
2020-07-09Original Approval
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE is FDA application ANDA212678, sponsored by EDENBRIDGE PHARMS. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class II2026-01-21
Bisoprolol Fumarate and Hydrochlorothiazide tablets, USP, 2.5 mg/6.25 mg, 100-count bottle, Rx Only, Manufactured by: UNcGMP Deviations: recall due to not meeting the N-Nitroso Bisoprolol impurity specification limits.
Class III2025-11-21
Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP, 2.5 mg/6.25 mg, packaged as (a) 30-count bottles, NDC-68462-87Cross Contamination with Other Products: Testing of reserve samples showed presence of traces of eze
Class III2023-10-20
Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP, 5mg/6.25mg, 100-count Bottle, RX only, Manufactured by: GlenmaFailed Impurities/Degradation Specifications
Class II2021-03-15
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE TABLETS 2.5 mg/6.25 mg, 100-count bottles, Rx Only, Distributed by: Teva PhaCGMP Deviations: Intermittent exposure to temperature excursion during storage.
Top Reported Reactions
1
HEADACHE
50 reports
2
FATIGUE
44 reports
3
DRUG INEFFECTIVE
43 reports
4
NAUSEA
42 reports
5
PRURITUS
39 reports
6
PAIN
38 reports
7
HYPERTENSION
37 reports
8
VOMITING
36 reports
9
DIARRHOEA
33 reports
10
RASH
33 reports